The pediatric ultra-hypermutated GBM presented in this case had multiple poor prognostic markers: MMR first/ POLE second deficiency, TP53 mutations, and lack of MGMT promoter methylation (Bouffet et al. 2016; Campbell et al. 2017). This evidence concerns the gene TP53 and glioblastoma.